| scholarly article | Q13442814 |
| P50 | author | Carlo Ferrari | Q37828540 |
| Carolina Boni | Q56813543 | ||
| P2093 | author name string | A Penna | |
| A Bertoletti | |||
| A Cavalli | |||
| F Fiaccadori | |||
| S Urbani | |||
| P Scognamiglio | |||
| R Boehme | |||
| R Panebianco | |||
| M Pilli | |||
| P2860 | cites work | Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues | Q28321734 |
| Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans | Q34195888 | ||
| Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen | Q34225571 | ||
| Virus proteins that counteract host immune defenses | Q35369721 | ||
| Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion | Q35596038 | ||
| Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen | Q36230704 | ||
| Molecular anatomy of viral persistence | Q36693882 | ||
| HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection | Q38319278 | ||
| Cytokine receptors encoded by poxviruses: a lesson in cytokine biology. | Q40422781 | ||
| Hepatitis B virus immunopathogenesis | Q40444875 | ||
| Hepatitis B virus genes and their expression in E. coli | Q41200439 | ||
| Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. | Q41715014 | ||
| Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. | Q41731198 | ||
| Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B | Q44846365 | ||
| Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells | Q45151385 | ||
| Serology of acute exacerbation in chronic hepatitis B virus infection | Q45259286 | ||
| Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection | Q45766634 | ||
| Comparative immunogenicity of hepatitis B virus core and E antigens | Q45847503 | ||
| Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. | Q45850067 | ||
| Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity | Q46094710 | ||
| Antiproliferative action of interferon-α requires components of T-cell-receptor signalling | Q59077517 | ||
| Single step separation of human T and B cells using AET treated SRBC rosettes | Q66887550 | ||
| In vitro immunotoxicity of +/- 2'-deoxy-3'-thiacytidine, a new anti-HIV agent | Q70460537 | ||
| A preliminary trial of lamivudine for chronic hepatitis B infection | Q71523548 | ||
| T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis | Q71611171 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lamivudine | Q422631 |
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 968-975 | |
| P577 | publication date | 1998-09-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B | |
| P478 | volume | 102 |
| Q73523468 | A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B |
| Q77310715 | A pill a day, or two, for hepatitis B? |
| Q45748181 | A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group |
| Q34716850 | A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection |
| Q46433832 | A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand |
| Q24810147 | Advances in immunomodulating therapy of HBV infection |
| Q38585657 | Advances in therapeutics for chronic hepatitis B. |
| Q44583432 | Antiviral T-cell responses and therapy in chronic hepatitis B. |
| Q37356804 | Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial |
| Q44314898 | Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model |
| Q36007344 | Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? |
| Q35883375 | Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand |
| Q43261074 | Association between polymorphism of tumor necrosis factor-alpha promoter and response to lamivudine treatment in patients with chronic hepatitis B. |
| Q35574310 | Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load |
| Q31431612 | Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis |
| Q34626075 | Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy |
| Q35784804 | Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load |
| Q90479796 | Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection |
| Q36099102 | Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein |
| Q34687438 | Chronic hepatitis B: current and future treatment options |
| Q40789349 | Chronic hepatitis B: new therapies on the horizon? |
| Q83390610 | Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate |
| Q36268376 | Clevudine for the treatment of chronic hepatitis B virus infection |
| Q42670565 | Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. |
| Q33872988 | Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B. |
| Q34086032 | Clinical potential of emerging new agents in hepatitis B. |
| Q51419221 | Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. |
| Q43064406 | Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model |
| Q44118743 | Combination therapy for children with chronic hepatitis B virus infection |
| Q38075796 | Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. |
| Q34391476 | Combination treatment in HBeAg-negative chronic hepatitis B. |
| Q45740632 | Combined interferon and lamivudine therapy: is this the treatment of choice for patients with chronic hepatitis B virus infection? |
| Q34556313 | Comparative pathogenesis of HBV and HCV. |
| Q44475703 | Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. |
| Q43824972 | Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy |
| Q35571573 | Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus |
| Q43466658 | Cure for immune-tolerant hepatitis B in children: is it an achievable target with sequential combo therapy with lamivudine and interferon? |
| Q34207450 | Current Options for the Therapy of Chronic Hepatitis B Infection |
| Q45743160 | Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings |
| Q33747793 | Decreased Ratio of Treg Cells to Th17 Cells Correlates with HBV DNA Suppression in Chronic Hepatitis B Patients Undergoing Entecavir Treatment |
| Q45204400 | Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans |
| Q40997829 | Dendritic cell-based vaccination with lentiviral vectors encoding ubiquitinated hepatitis B core antigen enhances hepatitis B virus-specific immune responses in vivo |
| Q37274697 | Design of therapeutic vaccines: hepatitis B as an example |
| Q51600138 | Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. |
| Q36474240 | Diminished Proliferation of Human Immunodeficiency Virus-Specific CD4+T Cells Is Associated with Diminished Interleukin-2 (IL-2) Production and Is Recovered by Exogenous IL-2 |
| Q45746042 | Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection |
| Q34661817 | Drug treatment of pediatric chronic hepatitis B. |
| Q35595469 | Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase |
| Q44193697 | Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation |
| Q41844881 | Dynamic Changes of Treg and Th17 Cells and Related Cytokines Closely Correlate With the Virological and Biochemical Response in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogues Treatment |
| Q89474335 | Dynamic of Immune Response induced in Hepatitis B Surface Antigen-transgenic Mice Immunized with a Novel Therapeutic Formulation |
| Q40968070 | Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. |
| Q37209954 | Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. |
| Q43993343 | Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion |
| Q42221830 | Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir |
| Q42593983 | Effects of lamivudine on the function of dendritic cells derived from patients with chronic hepatitis B virus infection |
| Q35915060 | Effects of telbivudine treatment on the circulating CD4⁺ T-cell subpopulations in chronic hepatitis B patients |
| Q43532970 | Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients |
| Q37688129 | End points of therapy in chronic hepatitis B. |
| Q45723463 | Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans |
| Q38306933 | Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine |
| Q44082487 | Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. |
| Q50585410 | Extended follow-up of anti-HBe-positive patients with chronic hepatitis B retreated with ribavirin and interferon-alpha. |
| Q43210150 | Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion |
| Q43851685 | Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis |
| Q79152244 | Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV |
| Q43039947 | First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline |
| Q41607528 | Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination |
| Q38295864 | HBV and the immune response |
| Q98612851 | HBVsvp-Pulsed Dendritic Cell Immunotherapy Induces Th1 Polarization and Hepatitis B Virus-Specific Cytotoxic T Lymphocytes Production |
| Q44472040 | HBcAg-specific CD8 T cells play an important role in virus suppression, and acute flare-up is associated with the expansion of activated memory T cells |
| Q40480304 | HIV Suppression Restores the Lung Mucosal CD4+ T-Cell Viral Immune Response and Resolves CD8+ T-Cell Alveolitis in Patients at Risk for HIV-Associated Chronic Obstructive Pulmonary Disease. |
| Q36614504 | Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. |
| Q33947160 | Hepatitis B e antigen seroconversion: effects of lamivudine alone or in combination with interferon alpha |
| Q34269640 | Hepatitis B infection in China |
| Q34807240 | Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. |
| Q37033272 | Hepatitis B virus (HBV)-specific T-cell responses to recombinant HBV core protein in patients with normal liver function and co-infected with chronic HBV and human immunodeficiency virus 1 (HIV-1) |
| Q37284817 | Hepatitis B virus DNA is more powerful than HBeAg in predicting peripheral T-lymphocyte subpopulations in chronic HBV-infected individuals with normal liver function tests |
| Q36422622 | Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. |
| Q44507323 | Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. |
| Q83352950 | Hepatitis B virus infection |
| Q44518699 | Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape |
| Q38046619 | Hepatitis B virus: from immunobiology to immunotherapy |
| Q35597143 | High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B |
| Q24814210 | High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial |
| Q33950164 | High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation |
| Q43172082 | Higher pretherapy and significant decrease during the first 12 months of therapy in serum laminin levels may associate with hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with lamivudine |
| Q37611853 | Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus |
| Q34022674 | How can the cellular immune response control hepatitis B virus replication? |
| Q44111673 | How long to treat chronic hepatitis B virus infection with lamivudine? |
| Q36447548 | IL-12-Dependent Cytomegalovirus-Specific CD4+ T Cell Proliferation, T-bet Induction, and Effector Multifunction during Primary Infection Are Key Determinants for Early Immune Control |
| Q34742036 | Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy |
| Q35005251 | Immune downregulation leads to upregulation of an antiviral response: a lesson from the hepatitis B virus |
| Q55257705 | Immune responses of human T lymphocytes to novel hepatitis B virus-derived peptides. |
| Q36388375 | Immune system and hepatitis B virus infection |
| Q33867720 | Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection |
| Q34365631 | Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection |
| Q34344082 | Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections |
| Q34470578 | Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. |
| Q36073739 | Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections |
| Q44151378 | Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers |
| Q34562294 | Immunology of hepatitis B infection |
| Q29618957 | Immunology of hepatitis B virus and hepatitis C virus infection |
| Q36821357 | Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model |
| Q35621705 | Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection |
| Q38550639 | Immunopathogenesis of hepatitis B persistent infection: implications for immunotherapeutic strategies |
| Q35621639 | Immunopathogenesis of hepatitis B. |
| Q34005309 | Immunopathogenesis of viral hepatitis |
| Q36797085 | Immunoregulation of hepatitis B virus infection--rationale and clinical application |
| Q34189149 | Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future |
| Q33370720 | Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients |
| Q33978910 | In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir |
| Q45722166 | Induction of antibodies to the PreS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens |
| Q80594566 | Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers |
| Q39953129 | Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15 cells. |
| Q79447368 | Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B |
| Q39907819 | Inhibition of woodchuck hepatitis virus gene expression in primary hepatocytes by siRNA enhances the cellular gene expression |
| Q59351616 | Insights From Antiviral Therapy into Immune Responses to HBV and HCV Infection |
| Q40969500 | Interferon-alpha response in chronic hepatitis B-transfected HepG2.2.15 cells is partially restored by lamivudine treatment |
| Q33894481 | Intrahepatic T cells in hepatitis B: viral control versus liver cell injury |
| Q40961740 | Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign? |
| Q54217690 | Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? |
| Q44114315 | Lamivudine and famciclovir combination therapy with or without addition of interferon-alpha-2b for HBeAg-positive chronic hepatitis B: a pilot study |
| Q24246121 | Lamivudine for chronic hepatitis B in adults |
| Q33947173 | Lamivudine for hepatitis B in clinical practice |
| Q45457655 | Lamivudine monotherapy in children with immune-tolerant chronic hepatitis B virus |
| Q46775423 | Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity |
| Q33706739 | Lamivudine. A review of its therapeutic potential in chronic hepatitis B. |
| Q44014358 | Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study |
| Q34880843 | Lamivudine: in children and adolescents with chronic hepatitis B virus infection |
| Q28372760 | Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine |
| Q36773747 | Management of hepatitis B: summary of a clinical research workshop |
| Q35621726 | Management of the patient with hepatitis B virus-related cirrhosis |
| Q33959006 | Management of viral hepatitis B. |
| Q35105712 | Mathematical modeling of viral kinetics: a tool to understand and optimize therapy |
| Q33867509 | Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B |
| Q98185008 | Multiple roles for hepatitis B and C viruses and the host in the development of hepatocellular carcinoma |
| Q34330228 | Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil |
| Q38180981 | New therapeutic vaccination strategies for the treatment of chronic hepatitis B. |
| Q33988066 | Nucleoside analogues in the treatment of chronic hepatitis B. |
| Q91898375 | On the future of therapeutic vaccination in chronic hepatitis B |
| Q97537414 | Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients |
| Q34975716 | Parallel decline of CD8+CD38+ lymphocytes and viremia in treated hepatitis B patients |
| Q28742762 | Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection |
| Q52928127 | Pathogenesis of hepatitis B virus infection. |
| Q37267440 | Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load |
| Q44618430 | Plasma pituitary adenylate cyclase activating polypeptide (PACAP) levels in chronic hepatitis B patients under lamivudine treatment |
| Q34430261 | Postnatal acquisition of primary rhesus cytomegalovirus infection is associated with prolonged virus shedding and impaired CD4+ T lymphocyte function |
| Q28371774 | Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group |
| Q33947154 | Profound suppression of hepatitis B virus replication with lamivudine |
| Q38664504 | Prospects and progress of DNA vaccines for treating hepatitis B. |
| Q33970966 | Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? |
| Q56881048 | Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? |
| Q34462097 | Quantity and quality of virus-specific CD8 cell response: relevance to the design of a therapeutic vaccine for chronic HBV infection. |
| Q36423998 | Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections |
| Q44062995 | Recent progress and new trends in the treatment of hepatitis B. |
| Q33211869 | Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy |
| Q40780186 | Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse. |
| Q47566400 | Reduced therapeutic effect of antiviral drugs in patients with hepatitis B virus reactivation after hematopoietic stem cell transplantation |
| Q45730726 | Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12. |
| Q44106952 | Remission of severe aplastic anemia associated with hepatitis B virus infection after viral clearance: potential role of lamivudine |
| Q34619603 | Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection |
| Q35980473 | Resistance to lamivudine therapy: is there more than meets the eye? |
| Q44653858 | Response to Lamivudine Treatment in Children with Chronic Hepatitis B Virus Infection |
| Q43504143 | Safe vaccination against hepatitis B virus and discontinuation of hepatitis B immune globulin treatment in a liver transplanted patient |
| Q35741969 | Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion |
| Q37003023 | Substance abuse, HIV-1 and hepatitis |
| Q43952840 | Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment |
| Q58622879 | Summary of the first international symposium on viral hepatitis |
| Q31906856 | Suppression of hepatitis B virus replication mediated by hepatitis A-induced cytokine production |
| Q34550760 | T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control |
| Q36981671 | T-regulatory lymphocytes and chronic viral hepatitis |
| Q34409291 | Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo |
| Q34362568 | Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil |
| Q35726960 | The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis |
| Q74780517 | The Role of CD4(+) and CD8(+) T Cells in Controlling HIV Infection |
| Q37293650 | The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients |
| Q44071057 | The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine |
| Q45734004 | The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication |
| Q33787525 | The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection |
| Q38636988 | Therapeutic strategies for a functional cure of chronic hepatitis B virus infection |
| Q34764822 | Therapeutic vaccination against chronic viral infections |
| Q37611862 | Therapeutic vaccination and novel strategies to treat chronic HBV infection |
| Q36689035 | Therapeutic vaccination in chronic hepatitis B virus carriers |
| Q43918478 | Therapeutic vaccination in chronic hepatitis B. |
| Q45399116 | Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine |
| Q36382226 | Therapy of hepatitis B -- viral suppression or eradication? |
| Q44039658 | Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. |
| Q90681211 | Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response |
| Q35023542 | Towards immunotherapy for chronic hepatitis B virus infections |
| Q58882255 | Towards personalized medicine in chronic HBV patients? |
| Q44583424 | Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. |
| Q35160324 | Translation of immunological knowledge into better treatments of chronic hepatitis B. |
| Q34547915 | Treatment of chronic hepatitis B. |
| Q43173401 | Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12. |
| Q36871085 | Treatment options for hepatitis B. |
| Q36667147 | Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B. |
| Q34105379 | Type 1/Type 2 immunity in infectious diseases |
| Q37195244 | Understanding the immunopathogenesis of chronic hepatitis B virus: an Asian prospective. |
| Q33988059 | Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection |
| Q33948393 | Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B. |
| Q33549555 | Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48. |
| Q74645306 | What once was lost, now is found: restoration of hepatitis B-specific immunity after treatment of chronic hepatitis B |
| Q77886843 | [New therapeutic possibilities in the treatment of hepatitis B] |
Search more.